Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Frequently asked questions
What sector does Aelis Farma SA (AELIS) operate in?
Aelis Farma SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Aelis Farma SA (AELIS) current stock price?
As of the latest data, Aelis Farma SA stock price is €1.11, with a previous close of €1.11.
What is Aelis Farma SA (AELIS) current market capitalization?
Aelis Farma SA market cap is approximately 15.13 million.
What is Aelis Farma SA (AELIS) Earnings Per Share (EPS)?
The trailing EPS is -€0.47, and the forward EPS is €0.17.
Does Aelis Farma SA (AELIS) pay dividends?
No. Aelis Farma SA does not pay a dividend.
When is Aelis Farma SA (AELIS) next earnings report?
Aelis Farma SA is expected to release its next earnings report on June 30, 2026.
What is Aelis Farma SA (AELIS) beta (volatility) score?
Aelis Farma SA has a beta of 0.622, indicating lower volatility than the overall market.
